NovellusDx Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 59
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $57M
Latest Deal Amount
  • Investors
  • 14

NovellusDx General Information

Description

Operator of a clinical-stage biotechnology company intended to develop highly selective medicines for functionally & genomically defined cancer patients. The company's platform recapitulates naturally occurring mutations in vitro and tests their effect on signaling pathway activity and their response to different compounds, helping biopharma companies identify new target mutations and expanded subgroups of cancer patients to respond to existing therapies.

Contact Information

Website
www.novellus.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Ein Karem
  • Jerusalem
  • Israel

NovellusDx Timeline

2017201820192020
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NovellusDx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series C) 21-Sep-2020 $57M 000.00 Completed Clinical Trials - Phase 1
6. Merger/Acquisition 17-Dec-2018 Cancelled Clinical Trials - Phase 1
5. Later Stage VC 30-Apr-2018 000 000.00 Completed Clinical Trials - Phase 1
4. Grant 31-Jan-2017 00000 000.00 Completed Clinical Trials - Phase 1
3. Later Stage VC 22-Jun-2016 000.00 000.00 Completed Clinical Trials - Phase 1
2. Seed Round 01-Jan-2014 $1.14M $5.14M Completed Clinical Trials - Phase 1
1. Seed Round 01-Jul-2013 $4M $4M Completed Clinical Trials - Phase 1
To view NovellusDx’s complete valuation and funding history, request access »

NovellusDx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a clinical-stage biotechnology company intended to develop highly selective medicines for functionally & gen
Drug Discovery
Jerusalem, Israel
59 As of 2020
000.00
00000000000 000.00

00 00000

do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud
0000 000000000
Copenhagen, Denmark
00 As of 0000
0000
00000000000 0000

00000000

tion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit
0000 000000000
Roseville, MN
00 As of 0000
000.00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NovellusDx Competitors (61)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
IO Biotech Venture Capital-Backed Copenhagen, Denmark 00 0000 00000000000 0000
00000000 000000000 Formerly VC-backed Roseville, MN 00 000.00 000000&0 000.00
000000000 00000000 Venture Capital-Backed South San Francisco, CA 00 000.00 000000000 - 000.00
000000000 Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000000 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 61 competitors. Get the full list »

NovellusDx Executive Team (8)

Name Title Board Seat Contact Info
Michael Vidne Ph.D Chief Executive Officer
Gabi Tarcic Ph.D Chief Technology Officer
Yaron Shimon Controller & Chief Accounting Officer
Mandy Gaziel Director, Quality Management
Shuki Sheinman Vice President, Research & Development
You’re viewing 5 of 8 executive team members. Get the full list »

NovellusDx Board Members (7)

Name Representing Role Since
Asaf Shinar Pontifax Venture Capital Board Member 000 0000
Charles Woler MD Self President of the Board 000 0000
Erez Chimovits OrbiMed Board Member 000 0000
Heiner Dreismann NovellusDx Board Member 000 0000
Ran Nussbaum Pontifax Venture Capital Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

NovellusDx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NovellusDx Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
Novartis Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
SR One Corporate Venture Capital Minority 000 0000 000000 0
Wellington Management Asset Manager Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Ready to get started?

Request a free trial